214 related articles for article (PubMed ID: 23404115)
1. The effect of the oral PKC β inhibitor ruboxistaurin on vision loss in two phase 3 studies.
Sheetz MJ; Aiello LP; Davis MD; Danis R; Bek T; Cunha-Vaz J; Shahri N; Berg PH;
Invest Ophthalmol Vis Sci; 2013 Mar; 54(3):1750-7. PubMed ID: 23404115
[TBL] [Abstract][Full Text] [Related]
2. Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study 2.
Aiello LP; Vignati L; Sheetz MJ; Zhi X; Girach A; Davis MD; Wolka AM; Shahri N; Milton RC;
Retina; 2011 Nov; 31(10):2084-94. PubMed ID: 21862954
[TBL] [Abstract][Full Text] [Related]
3. Effect of ruboxistaurin (RBX) On visual acuity decline over a 6-year period with cessation and reinstitution of therapy: results of an open-label extension of the Protein Kinase C Diabetic Retinopathy Study 2 (PKC-DRS2).
Sheetz MJ; Aiello LP; Shahri N; Davis MD; Kles KA; Danis RP;
Retina; 2011 Jun; 31(6):1053-9. PubMed ID: 21386766
[TBL] [Abstract][Full Text] [Related]
4. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy.
; Aiello LP; Davis MD; Girach A; Kles KA; Milton RC; Sheetz MJ; Vignati L; Zhi XE
Ophthalmology; 2006 Dec; 113(12):2221-30. PubMed ID: 16989901
[TBL] [Abstract][Full Text] [Related]
5. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.
Davis MD; Sheetz MJ; Aiello LP; Milton RC; Danis RP; Zhi X; Girach A; Jimenez MC; Vignati L;
Invest Ophthalmol Vis Sci; 2009 Jan; 50(1):1-4. PubMed ID: 18708615
[TBL] [Abstract][Full Text] [Related]
6. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial.
PKC-DMES Study Group
Arch Ophthalmol; 2007 Mar; 125(3):318-24. PubMed ID: 17353401
[TBL] [Abstract][Full Text] [Related]
7. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial.
PKC-DRS Study Group
Diabetes; 2005 Jul; 54(7):2188-97. PubMed ID: 15983221
[TBL] [Abstract][Full Text] [Related]
8. Effect of ruboxistaurin on the visual acuity decline associated with long-standing diabetic macular edema.
Sahu AK; Majji AB
Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6890; author reply 6890-1. PubMed ID: 21123772
[No Abstract] [Full Text] [Related]
9. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial.
Vinik AI; Bril V; Kempler P; Litchy WJ; Tesfaye S; Price KL; Bastyr EJ;
Clin Ther; 2005 Aug; 27(8):1164-80. PubMed ID: 16199243
[TBL] [Abstract][Full Text] [Related]
10. Sustained moderate visual loss as a predictive end point for visual loss in non-proliferative diabetic retinopathy.
Girach A; Aiello LP; Milton RC; Davis MD; Danis RP; Zhi X; Sheetz MJ; Vignati L;
Eye (Lond); 2009 Jan; 23(1):209-14. PubMed ID: 18989348
[TBL] [Abstract][Full Text] [Related]
11. Diabetic macular oedema and visual loss: relationship to location, severity and duration.
Gardner TW; Larsen M; Girach A; Zhi X;
Acta Ophthalmol; 2009 Nov; 87(7):709-13. PubMed ID: 19817721
[TBL] [Abstract][Full Text] [Related]
12. Long-term effect of intravitreal bevacizumab (avastin) in patients with chronic diffuse diabetic macular edema.
Kook D; Wolf A; Kreutzer T; Neubauer A; Strauss R; Ulbig M; Kampik A; Haritoglou C
Retina; 2008 Oct; 28(8):1053-60. PubMed ID: 18779710
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients.
Aiello LP; Clermont A; Arora V; Davis MD; Sheetz MJ; Bursell SE
Invest Ophthalmol Vis Sci; 2006 Jan; 47(1):86-92. PubMed ID: 16384948
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema.
Haritoglou C; Kook D; Neubauer A; Wolf A; Priglinger S; Strauss R; Gandorfer A; Ulbig M; Kampik A
Retina; 2006; 26(9):999-1005. PubMed ID: 17151486
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported visual function outcomes improve after ranibizumab treatment in patients with vision impairment due to diabetic macular edema: randomized clinical trial.
Mitchell P; Bressler N; Tolley K; Gallagher M; Petrillo J; Ferreira A; Wood R; Bandello F;
JAMA Ophthalmol; 2013 Oct; 131(10):1339-47. PubMed ID: 23974915
[TBL] [Abstract][Full Text] [Related]
16. Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema.
Strøm C; Sander B; Klemp K; Aiello LP; Lund-Andersen H; Larsen M
Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3855-8. PubMed ID: 16186374
[TBL] [Abstract][Full Text] [Related]
17. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE.
Nguyen QD; Brown DM; Marcus DM; Boyer DS; Patel S; Feiner L; Gibson A; Sy J; Rundle AC; Hopkins JJ; Rubio RG; Ehrlich JS;
Ophthalmology; 2012 Apr; 119(4):789-801. PubMed ID: 22330964
[TBL] [Abstract][Full Text] [Related]
18. Darapladib, a lipoprotein-associated phospholipase A2 inhibitor, in diabetic macular edema: a 3-month placebo-controlled study.
Staurenghi G; Ye L; Magee MH; Danis RP; Wurzelmann J; Adamson P; McLaughlin MM;
Ophthalmology; 2015 May; 122(5):990-6. PubMed ID: 25749297
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial.
Gillies MC; Sutter FK; Simpson JM; Larsson J; Ali H; Zhu M
Ophthalmology; 2006 Sep; 113(9):1533-8. PubMed ID: 16828501
[TBL] [Abstract][Full Text] [Related]
20. Changes in vision- and health-related quality of life in patients with diabetic macular edema treated with pegaptanib sodium or sham.
Loftus JV; Sultan MB; Pleil AM;
Invest Ophthalmol Vis Sci; 2011 Sep; 52(10):7498-505. PubMed ID: 21896838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
